RA
TELA icon

Royce & Associates’s TELA Bio TELA Stock Holding History

Royce & Associates’s Portfolio TELA Stock Details TELA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-1,000,064
Closed -$3.02M – 860
2024
Q4 		$3.02M Buy
+1,000,064
New +$2.81M 0.03% 566

Other funds holding TELA

EWM
Essex Woodlands Management The Woodlands, Texas $251M AUM 13.72% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
PCM
Perkins Capital Management Wayzata, Minnesota $107M AUM 82.62% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Royce & Associates's TELA Position: Q1 2025 in Review

Royce & Associates sold out of TELA Bio (TELA) in Q1 2025, closing a stake of 1,000,064 shares — an estimated $3.02M sold.

Royce & Associates first reported a position in TELA in Q4 2024 and held it in 1 quarter. The position peaked at $3.02M in Q4 2024. 50 funds tracked by Wall St. Rank hold TELA as of Q1 2025.

  • Royce & Associates reported no remaining TELA Bio position as of Q1 2025 after selling out during the quarter.
  • Royce & Associates sold 1,000,064 TELA Bio shares in Q1 2025, an estimated $3.02M.
  • Royce & Associates first reported a position in TELA Bio in Q4 2024 and held it in 1 quarter.
  • Royce & Associates's TELA Bio position peaked at $3.02M in Q4 2024.
  • 50 funds tracked by Wall St. Rank held TELA Bio as of Q1 2025.

Based on Royce & Associates's 13F filing for Q1 2025, filed 6 May 2025.